Supplemental
Capital expenditures incurred but not yet paid
Neurocrine Biosciences Capital expenditures incurred but not yet paid decreased by 12.5% to $1.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.1%, from $2.70M to $1.40M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionSupplemental
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates a growing pipeline of capital projects or equipment acquisitions that will require future cash settlement.
Detailed definition
This metric captures capital expenditures that have been committed to or incurred but for which cash payment has not yet...
Peer comparison
Commonly found in the supplemental cash flow disclosures of capital-intensive manufacturing firms.
Metric ID:
amd_capex_unpaidHistorical Data
13 periods
| Q2 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.10M | $1.60M | $2.80M | $600.00K | $200.00K | $100.00K | $1.60M | $1.10M | $2.20M | $1.40M | $2.70M | $1.60M | $1.40M |
| QoQ Change | — | -23.8% | +75.0% | -78.6% | -66.7% | -50.0% | >999% | -31.3% | +100.0% | -36.4% | +92.9% | -40.7% | -12.5% |
| YoY Change | — | — | — | -78.6% | — | — | — | +83.3% | >999% | -12.5% | +145.5% | +14.3% | -48.1% |
Range$100.00K – $2.80M
CAGR-12.6%
Avg YoY Growth+157.7%
Median YoY Growth+14.3%
Current Streak2 quarters decline
Capital expenditures incurred but not yet paid at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's capital expenditures incurred but not yet paid?
- Neurocrine Biosciences (NBIX) reported capital expenditures incurred but not yet paid of $1.40M in Q1 2026.
- How has Neurocrine Biosciences's capital expenditures incurred but not yet paid changed year-over-year?
- Neurocrine Biosciences's capital expenditures incurred but not yet paid decreased by 48.1% year-over-year, from $2.70M to $1.40M.
- What does capital expenditures incurred but not yet paid mean?
- Capital investments made during the period that have not yet been paid for in cash.